Effects of treatment with the atypical neuroleptic quetiapine on working memory function: a functional MRI follow-up investigation

BackgroundWorking memory as a part of higher-order executive functions is defined by the parallel storage and processing of information. Recent functional fMRI studies have revealed a functional, interregional disintegration of a neuronal network connecting cortical, subcortical and cerebellar regions in schizophrenic patients (SZ). Cognitive impairment in working memory is a core psychopathological correlate of schizophrenic symptoms. Atypical neuroleptics such as quetiapine have shown good efficacy in treating positive and negative symptoms. The presented study evaluated the impact of a neuroleptic steady state treatment with quetiapine on the altered working memory activation patterns in schizophrenia.MethodsPatients were examined by fMRI at baseline and after 12 weeks of steady state treatment with quetiapine. Matched healthy controls (HC) underwent baseline examination. In the scanner, stimuli were presented in a 2-back and 0-back condition of a working memory (wm) paradigm, whereby a degraded and a non-degraded version were used each time. Additionally, behavioural responses (reaction time to target stimuli and error ratio) were measured.ResultsAt baseline, healthy controls revealed increased activity in the frontal lobe, especially in regions of the prefrontal cortex. Compared to HC, SZ showed hypoactivation in the right dorsolateral prefrontal cortex (DLPFC) and the ventrolateral prefrontal cortex (VLPFC) bilaterally for the 2-back condition. In the 2-back degraded condition there was a hypoactivation in both, the right DLPFC and the VLPFC. Additionally, patients showed bilaterally decreased activation in the basalganglia in the 2-back and in the right caudatus in the 2-back degraded condition compared to healthy controls. After treatment with quetiapine, patients activations patterns were increased. The pre–post comparison of the 2-back condition revealed a significant increase of activation in the left VLPFC at a significance level of 0.001 (uncorrected). The 2-back degraded condition led to a significant activation pattern in the lingual gyrus and the right precuneus. In both wm conditions, at baseline there were no differences in reaction time but only a worse performance in SZ. After treatment, behavioural measurement of responses, including reaction time and performance, showed slight improvements in SZ, although these did not reach statistical significance.ConclusionsThe neuronal networks underlying working memory are clearly altered in schizophrenia. After 12 weeks of treatment with quetiapine monotherapy, patients showed significant clinical improvement and revealed increased BOLD activity in the VLPFC during a working memory task, although there was no improvement of cognitive performance.

[1]  N. Andreasen The Scale for the Assessment of Negative Symptoms (SANS): Conceptual and Theoretical Foundations , 1989, British Journal of Psychiatry.

[2]  J. Callicott,et al.  Functional lateralization of the sensorimotor cortex in patients with schizophrenia: effects of treatment with olanzapine , 2004, Biological Psychiatry.

[3]  B. Postle,et al.  Prefrontal cortical contributions to working memory: evidence from event-related fMRI studies , 2000, Experimental Brain Research.

[4]  S. Purdon Measuring neuropsychological change in schizophrenia with novel antipsychotic medications. , 2000, Journal of psychiatry & neuroscience : JPN.

[5]  M. Petrides Dissociable Roles of Mid-Dorsolateral Prefrontal and Anterior Inferotemporal Cortex in Visual Working Memory , 2000, The Journal of Neuroscience.

[6]  A. Malla,et al.  Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. , 2001, Journal of psychiatry & neuroscience : JPN.

[7]  D. Weinberger,et al.  Prefrontal function in schizophrenia: confounds and controversies. , 1996, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[8]  H. Möller Atypical neuroleptics: a new approach in the treatment of negative symptoms , 1999, European Archives of Psychiatry and Clinical Neuroscience.

[9]  R. Coppola,et al.  Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. , 2000, Cerebral cortex.

[10]  R. Coppola,et al.  Physiological characteristics of capacity constraints in working memory as revealed by functional MRI. , 1999, Cerebral cortex.

[11]  Steven Warach,et al.  Schizophrenic subjects activate dorsolateral prefrontal cortex during a working memory task, as measured by fMRI , 1999, Biological Psychiatry.

[12]  M. Egan,et al.  Complexity of prefrontal cortical dysfunction in schizophrenia: more than up or down. , 2003, The American journal of psychiatry.

[13]  Alexander L. Miller,et al.  Does cognitive function improve with quetiapine in comparison to haloperidol? , 2002, Schizophrenia Research.

[14]  T. Robbins,et al.  The case of frontostriatal dysfunction in schizophrenia. , 1990, Schizophrenia bulletin.

[15]  S. Kiebel,et al.  An Introduction to Random Field Theory , 2003 .

[16]  I. Kiss,et al.  Improvement in cognitive functioning in patients with first-episode psychosis during treatment with quetiapine: An interim analysis , 2002, British Journal of Psychiatry.

[17]  J. Kelsoe,et al.  Genetics of affective disorders , 2001, European Neuropsychopharmacology.

[18]  T. Sharma Quetiapine – efficacy in different domains , 2001, European Neuropsychopharmacology.

[19]  Steven C. R. Williams,et al.  Cortical effects of quetiapine in first-episode schizophrenia: A preliminary functional magnetic resonance imaging study , 2004, Biological Psychiatry.

[20]  Ravi S. Menon,et al.  Imaging function in the working brain with fMRI , 2001, Current Opinion in Neurobiology.

[21]  E. Bullmore,et al.  Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Jonathan D. Cohen,et al.  Prefrontal cortex dysfunction mediates deficits in working memory and prepotent responding in schizophrenia , 2003, Biological Psychiatry.

[23]  P. Goldman-Rakic Working memory dysfunction in schizophrenia. , 1994, The Journal of neuropsychiatry and clinical neurosciences.

[24]  Peter Stoeter,et al.  Altered effective connectivity during working memory performance in schizophrenia: a study with fMRI and structural equation modeling , 2003, NeuroImage.

[25]  J. Schmahmann,et al.  Cerebellar cognitive affective syndrome. , 1997, International review of neurobiology.

[26]  H. Möller,et al.  Cerebral changes and cognitive dysfunctions in medication-free schizophrenia - an fMRI study. , 2008, Journal of psychiatric research.

[27]  Gregory G Brown,et al.  Spatial working memory among middle-aged and older patients with schizophrenia and volunteers using fMRI , 2004, Schizophrenia Research.

[28]  H. Möller,et al.  Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms , 2005, European Archives of Psychiatry and Clinical Neuroscience.

[29]  Bruce R. Rosen,et al.  Activity in Ventrolateral and Mid-Dorsolateral Prefrontal Cortex during Nonspatial Visual Working Memory Processing: Evidence from Functional Magnetic Resonance Imaging , 2000, NeuroImage.

[30]  J. Cohen,et al.  Selective deficits in prefrontal cortex function in medication-naive patients with schizophrenia. , 2001, Archives of general psychiatry.

[31]  Jonathan D. Cohen,et al.  Dissociating working memory from task difficulty in human prefrontal cortex , 1997, Neuropsychologia.

[32]  S. Potkin,et al.  Frontostriatal disorder of cerebral metabolism in never-medicated schizophrenics. , 1992, Archives of general psychiatry.

[33]  L. Arvanitis,et al.  Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo , 1997, Biological Psychiatry.

[34]  C. Fahim,et al.  Restoration of frontal activation during a treatment with quetiapine: an fMRI study of blunted affect in schizophrenia , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[35]  C. M. Parkes Psychiatric Problems Following Bereavement by Murder or Manslaughter , 1993, British Journal of Psychiatry.

[36]  C. Fahim,et al.  Differential Hemodynamic Brain Activity in Schizophrenia Patients With Blunted Affect During Quetiapine Treatment , 2005, Journal of clinical psychopharmacology.

[37]  V. Peralta,et al.  Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study , 2001, Schizophrenia Research.

[38]  O. Sabri,et al.  Cerebral correlates of selective attention in schizophrenic patients with formal thought disorder: a controlled H2 15O-PET study , 2002, Psychiatry Research: Neuroimaging.

[39]  M. Egan,et al.  Comparison of Cognitive Performances During a Placebo Period and an Atypical Antipsychotic Treatment Period in Schizophrenia: Critical Examination of Confounds , 2003, Neuropsychopharmacology.

[40]  S. Rauch,et al.  Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal cortex and basal ganglia during working memory performance , 2000, Biological Psychiatry.